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Abstract Microneedles can be representative for paradigm shift of drug 
delivery from patient non-compliant parenteral injections to patient compliant 
drug delivery system, which can be utilized for administration of vaccines 
particularly along with macromolecular/micromolecular drugs. The concept of 
microneedles came into existence many decades ago but the use of microneedles 
to achieve efficient delivery of drugs into the skin became subject of research 
from mid of 1990’s. Various types of microneedles were utilized to enhance 
delivery of drugs and vaccines including solid microneedles for pre-treatment 
of skin to enhance drug permeability, dissolvable polymeric microneedles 
encapsulating drugs, microneedles coated with drugs and hollow microneedles 
for infusion of drugs through the skin. Microneedles have shown promising 
delivery of vaccines through skin in literature. But the successful utilization 
of this system for vaccine drug delivery mainly depends on design of device 
to facilitate microneedle infusion, vaccine stability and storage in system, 
recovery of skin on removal of microneedle and improved patient compliance. 
This article reviews the conventional and advanced methods of vaccine drug 
deliver, microneedles for drug delivery, types of microneedles, advantages of 
microneedles and potential of microneedles for vaccine drug delivery.
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1. INTRODUCTION
Vaccines are the class of matter which unveil the immunologically arbitrated 
resistance for the disease but is not mandatory in case of an infection. They 





or encoding DNA for different antigenic proteins of pathogens. The vaccines 
subunit type is specially choosey and particular while having interaction with 
antibodies which generally fail to present these interactions in cases like 
alterations for epitopic recognition core of poorly immunogenic and also of 
antibody. Yet, selectiveness and specifies of infectious organisms sub units like 
carbohydrates, proteins could be altered in case of manufacturing tough and 
protracted immunological response thru providing them to immune system 
in a manner that a exact, robust immune response is developed. Epitopes 
could as well trigger the production of vaccines merely not in contradiction of 
diseases causing infection, however as well in the case of prolonged diseases 
like cancer or hepatitis C. In a manner for inculcating a dominant protecting 
resistance, these vaccines necessitate enhancing by mediators acknowledged 
as ADJUVANTS. Adjuvant is supposed to present their action via creating 
complex through a media tor that need to be transported from immune gens 
which are slowly released(Song, 2012).
The idea of providing vaccines through skin is a very primitive technique. 
Initially, the Chinese used the technique which was then called as variolation in 
which the small pox virus i.e. variola virus was dragged out of disease-ridden 
patients and then abraded between the skin of a healthy individuals. The idea 
was to purposely incite smallpox infection which may be mild, would offer a 
protective mechanism contrary to potentially extra powerful natural infection. 
Being effective in number of cases, its use was associated with substantial 
death. Finally the word vaccination was termed as the outcome of Edward 
Jenner’s affirmation which states scraping of allied however not much virulent 
vaccinia virus (cowpox virus), inside the skin can perhaps efficaciously hinder 
small pox virus contagion. Now a days, vaccination of small pox is carried out 
via injecting vaccine virus in the skin by method of branched Needles. The 
things about which the early Chinese or Edward Jenner and his supporters 
were not aware was that the human skin is highly rigid immune prompting 
tissue because of the vast accumulation of dominant antigen-presenting cells 
present inside the human skin, specifically epidermal Langerhans Cells, dermal 
dendritic cells. During accumulation for smallpox, numerous other vaccines 
were used on the skin by means of traditional syringes and needles, as stated 
in the mantoux technique. The above mentioned technique was executed by 
introducing the regular 26 or 27 Gauze needle inside the skin at a very small 
angle having a bevel up. Very careful insertion of needle is done adequately 
inside the skin for complete safeguard of bevel and 0.1 millilitre fluid is inserted 
inside the skin which results in the creation of the elevated itchy (pruritic) area. 
This practise demand side-range training and is demanding to be completed 







Vaccine transport systems include liposomes, microparticles, emulsions, 
immune-stimulating complexes ISCOMs. The Immunostimulatory adjuvants 
in case of pathogens are the preserved molecular designs which enhance 
immunity being recognized through the receptors such as “Toll” receptors 
sited primarily on dendritic cells and B cells present in mammals (CpG in 
unmethylated form which coats DNA) (Schwendener, 2014). Adjuvants 
vitalize immunostimulatory effect produced by antigen even though they are 
non-immunogenic, risk-free, and perishable by its own. Salts of Aluminium 
like Al(OH)3, AlPO4; oily emulsions like Freunds partial adjuvant; particulate 
material including ISCOMs; artificial polynucleotides are extraneous forms of 
adjuvants (Schwendener, 2014, Apostolopoulos, 2013).
2. CHARACTERISTICS FOR AN IDEAL VACCINE (SUH, 2014):
• The vaccine should be non-toxic or non-pathogenic which means 
vaccine is safe. 
• The level of side effects in case of normal individuals should be very 
low.
• Individuals having impaired immune system should not suffer any 
problem due to this.
• In case of vaccinated individuals or individuals with live vaccine, there 
should be no spreading of any infection.
• It should yield an extended long-term humoral as well as cellular 
immunities.
• The method for vaccination must be easy.
• The vaccine must be inexpensive.
• It must not infect the environment.
• The vaccine must be effective.
3. CONVENTIONAL SYSTEMS FOR DELIVERY OF VACCINES
The various types of vaccine delivery systems are:
3.1 Liposomes (phospholipid based vesicles) in 1970s liposome were widely 
in use for the delivery of drugs targeting locations inside the body. The 
supplementary favourable feature of this method is its immunoadjuvant 
action that is revealed to show cell-mediated immune responses and/or 
humoral responses in lieu of liposomal trapped antigens without or with 
cytokines or more specific immunologically vitalmediators. Alternate 
methodology includes samalgamating antigens in the solid elements 





from peptides along with adjuvant Quil A. ISCOM components include 
lower strengths of adjuvants but thereafter substantially enhancing the 
immunogenicity of the antigen (Saroja, 2011).
3.2 The multiple antigen peptide approach (MAP) These are a type of 
dendrimers, which are intended for substituting the carrier proteins into 
a vaccine linked with peptide, having little fundamental unit which can 
intensify peptide antigens devoid of the short comings linked along 
the carriers of protein. The back ground of MAP is the central medium 
that consists of diverging trifunctional amino acids (lysine) having 
characteristics given below :(i) Non-immunogenic (ii) flexibility for 
incorporating numerous epitopes (iii) capability to strengthen the peptide 
antigens within a macromolecule (IV) available in case of chemical 
reactions. MAP (dendrimer) technique is being in effective use to inculcate 
immune reactions to antigens (Saroja, 2011).
3.3 Best vaccine for sever alailments is the live at tenuate derived from 
pathogen which could boost defensive immunity for antigens present upon 
a pathogen devoid of producing some kind of adverse effects. Hindrances 
in the growth of these vaccines, gave increment in the problems of raising 
the pathogen within the laboratory along with problems associated 
with killing of pathogen. To overcome these barriers the only approach 
which could be used is the introduction of pathogenic genes inside the 
non pathogenic organism. In case of expression for genes coding of the 
antigens is done/ served by non-virulent organism (recombinant virus). 
The benefit of this is that the recombinant virus immediately develops 
foreign antigen that is delivered to individual’s immune system. There are 
various vectors that have been examined in the development of vaccines 
and include avipox virus, adenovirus, alpha virus, enterovirus vectors, 
vaccinia virus Ankara and vaccinia virus. (Apostolopoulos, 2013).
3.4 Inoculation with non-replicating plasmid DNA (Naked DNA) coding 
for the viral proteins might be advantageous for the purpose of vaccines, as 
there is no infective agent used, so as such there is no need of accumulating 
the virus particles and the choice for determining factor is allowed. In case 
of the animal models rigid immune responses was developed however, 
they were not possible to translate within the human clinical trials. The 
result of this was the necessity of distribution methods for DNA and 
likewise in vitro, in vivo electroporation, Biojector 2000 and gene-gun 
were manufactured. Other methods for ease included the non-viral vectors 
and the receptor linked uptake for DNA within the cells (Chen, 2015).
3.5 Cell penetrating peptides (CPP) or membrane translocating peptides 







inside the cytoplasm of the cells. CPP are capable for transporting a number 
of antigens which include DNA, drugs, proteins, peptides, RNA and virus 
particles within the cells. CPP are in fact - (i) human immunodeficiency 
virus attained from TAT is a trans activator for the transcriptional protein 
(ii) penetrating obtained from the Drosophila Antennapedia domain has 
been used for the transport of antigens with robust cellular and antibody 
response initiation (Apostolopoulos, 2013).
3.6 Along with this a compilation of other techniques for vaccine transfer 
have shown prodigiouspotential in case of animal models and also in 
human clinical trials. These techniqueencompass the requirement of nano 
particles, virus-like particles and utilization of ex vivo produced monocyte 
derived dendritic cells and target antigens for dendritic cell receptors 
which are CIRE, c-type lectin receptors, Clec2, Clec12A and Clec12B, 
DC-STAMP, DNGR-1, DEC205, DC-SIGN, dectin-1, dectin-2, DCIR, 
DC-SIGNR, FIRE, Fc receptor, F4/80 receptor, Langerin, L-SIGN, LOX1, 
MGL, mannose receptor, scavenger receptor. Now a days the increase in 
knowledge regarding toll-like receptor (TLR) targeting and stimulation for 
DCs through TLR has helped in this area. These TLR ligands inside mice 
initiate DCs and trigger immune responses, though, no significant TLR-
targeting vaccine trials have/had been completed in humans and its not sure 
that TLR targeting methodology would offer considerable advantageous 
outcome in human beings as seen in the case of mice. Moreover, various 
targeting antigens of chemokine receptors on DCs (CCR1, CCR2, 
CCR5, CCR6, CXCR1, CXCR4) have shown to yield robust immune 
responses both invitro and invivo. However, bacterial toxins along with 
DC binding peptides targeted antigens to DCs lacking the requirement 
of DC receptor targeting. In case of distinctive apprehension for vaccine 
delivery, the current techniques for live- killed/weakened bacterial vectors, 
nano particle dependent vaccines, artificial transporters, cholera toxin 
subunit B as an adjuvant and in case of GAVI vaccination programs were 
widely studied (Apostolopoulos, 2013).
3.7 Microspheres
 The biodegradable and biocompatible copolymer poly (DL-lactide-
co-glycolide) [DL-PLG] was used to develop the vaccines containing 
microspheres. Subcutaneous immunization in mice was done by using 
1- to 10-microns of microspheres which consisted of a toxoid vaccine of 
staphylococcal enterotoxin B (SEB) which fortified to 500-fold increase 
in strength of nerve impulses for the allocating antitoxin response. A 
Constructive adjuvantaction was dependent on the microspheres whose 





the presence of antigen inside the particles. The rate at which DL-PLG 
biodegradation takes place is used for determination of the ratio of lactide 
to glycolide, and in case of co-injection of SEB toxoid microspheres 
articulated with two dissimilar DL-PLG ratios encouraged for both 
a primary and an enhanced reaction of secondary antitoxin response. 
When DL-PLG was imported by the oral or intratracheal (IT) route, 
the microencapsulated SEB toxoid was observed to be beneficial in 
the initiation of concomitant circulation and dispersion of mucosal 
antibody responses. Female rhesus macaques were vaccinate during a 
microencapsulated simian immunodeficiency virus (SIV) serum was 
generated for higher concentration of distributing anti-SIV antibodies, and 
consequent oral or IT boost, particular antibodies were obtained in vaginal 
wash fluids. Vaginal challenge with feasible homologous SIV gave rise to 
infection of three out of four non immunized however only one out of seven 
microsphere-immunized macaques. Therefore, DL-PLG microspheres are 
capable technique for the transport of vaccines, assimilation of adjuvant 
motion with metered release and effective demonstration to mucosally 
associated lymphoid tissues (MALT) (Stanley, 2013). Table 1 depicts data 
on marketed vaccines based on conventional delivery systems as per FDA. 
Table 1: Some commercial vaccine formulations (http://www.who.int/)
S. No Vaccine Used Company name Description
1 Zostavax Merck & Co Shingles, herpes
2 Prevnar 7 Pfizer Pneumococcal infection, otitis media
3 Fluzone Sanofi Influenza
4 Menactra Sanofi Meningitis
5 Adacel Sanofi Diphtheria, pertussis / whooping cough, 
tetanus
6 MMR- II Merck & co Measles, mumps, rubella
7 Boostix GlaxoSmithKline Diphtheria, pertussis / whooping cough, 
tetanus
8 Biothax Emergent biosolutions Anthrax
9 Prevnar 13 Pfizer Pneumococcal infection
10 PENTAct-HIB Sanofi Haemophillus influenza type b, polio, 
tetanus, whooping cough/ pertussis, 
Diphtheria.
11 Gardasil Merck & co Human papillomavirus








S. No Vaccine Used Company name Description
13 Hepatitis 
vaccine
GlaxoSmithKline hepatitis A, hepatitis B
14 Celtura Novartis Swine flu
15 Varivax Merck & co Varicella virus
16 Cervarix GlaxoSmithKline HPV
17 Rota teq Merck & co Rotavirus gastroenteritis
18 Synflorix GlaxoSmithKline Pneumococcal infection, otitis media
19 Rotarix GlaxoSmithKline Rotaviral gastroenteritis
20 Pneumovax Merck & co Pneumococcal infection
4.  ADVANCED CARRIERS FOR VACCINE DELIVERY: 
MICRONEEDLES
4.1 Introduction
The notion of the bunch of small sized needles for the purpose of drug delivery 
dates back to 1976 and a patent was filed for this (filed 1971) by Gerstel and Place 
at Alza Corp. 22. This patent was claimed for a device used for drug delivery 
and had small projections (i.e. Microneedles) and also had a drug reservoir. 
Microneedles are generally solid or hollow because of their small size that is 
capable to penetrate stratum corneum. The Delivery of drug or medicament from 
such devices can occur through diffusion or by convention by the use of the 
force for backing of the reservoir (Courtenay, 2016). For the achievement of 
physiologically related supply rates the micro needle dependent drug transport 
is normally done with cluster of needles for a specific area. For Insertion of 
micro needle arrays by a huge amount of needles within the skin by avoiding 
the use of a distinct insertion tool (e.g. a high-velocity plunger) requires the 
reduced force for insertion needed to pierce the tissue. Along with this patches 
are required for delivering drug, so for this it requires penetration regardless 
of the skin type/age of the subject and the humidity present. The penetration 
forces can be affected or changed by these above factors. Hence, it’s sensible 
to consider that defence criteria’s of 3–5 intervals might be mandatory. When 
shown practically, the insertion of Microneedles inside the skin is strongly 
connected with the interfacial area amongst the skin and Microneedles. If the 
interfacial area is small then the insertion force will be low. It can also be said 
that the use of sharp needle can be negligible in case of interfacial area so it 
will pierce the tissue in comparison to blunt needle. (Woolfson, 2012). The 
evolution of Microneedles in case of delivering the vaccines besides pandemic 





case of solid state vaccine transfer preparations might result in a provocatively 
improved shelf-life of delivery systems like these because of their inherently 
enhanced durability in case of solid state protein preparations in comparison to 
their traditional corresponding solutions. This results in more adequate supplies 
and capabilities for piling the stock which is highly required in case of vaccines 
in contrast to pandemic influenza are foreseen. Secondly, arrays of Micro needle 
can probably be self-administered and carefully thrown of, which might be Vital 
in the occasion of insufficiency of medical persons (Carey, 2014). 
4.2 Fabrication of Microneedles
Microneedles are developed on the criteria of micro scale (having 1 μm 
of diameter and extending from 1 to 100 μm in case of length) and this 
differentiates them from traditional needles. These are made up of various 
constituents like: glass, metals, polymers, silicon, silicon dioxide and other 
ingredients. Microneedles could be designed to be long enough so that they 
can penetrate the layer of skin (stratum corneum), avoiding the perforation 
of nerve endings which reduces the chances of any kind of infection, injury 
or pain (Apostolopoulos,2013). Intradermal delivery of vaccines can be 
facilitated by the prepared Microneedles which is generally not easy to 
achieve in case of large populations in a highly reproducible manner. Many 
micro needle production procedures are dependent on the traditional micro 
fabrication methods for adding, eliminating and replicating microstructures 
using photolithographic procedures, silicon etching, laser wounding, metal 
electroplating, metal electro polishing and micro molding (Jiskoot, 2012).
4.3 Drug delivery through Microneedles
Microneedles consist of the array of micro sized structured projections which 
are covered by a drug or vaccine which is applicable on the skin to distribute 
intradermal transport of active agents which else may not be able to cross 
stratum corneum. The transport of vaccines or drugs is not done by the process 
of diffusion as in case of transdermal delivery systems however the momentary 
mechanical interruption of the skin can lead to the placing of the drug or 
vaccine inside the epidermis layer, where it could reach easily to the specific 
site for its action. 
4.4 Types of Microneedles
Microneedles can be categorised as :
Solid Microneedles which can be used for tissue pre-treatment, Microneedles 







hollow Microneedles. Another categorisation of Microneedles normally used 
in literature is on the basis of their production methods which could be in-
plane or out-of plane microneedles (Jiskoot, 2012).
In-plane microneedles made to have the shaft which is parallel to the substrate 
layer. The benefit of this technique is the extent of the needle that can be very 
accuratelymetered. The drawback of this technique is that it hasproblem in 
developing a two dimensional arrays(Jiskoot, 2012). 
Out of-plane microneedles on the contrary, is a substrate projection and they 
are straight advancing to develop in arrays. Irrespective of the length and height 
ratios it becomes an essential task for developing these kind of needles. Other 
than these, beneficial criteria/level is to differentiate that the microneedles could 
be solid or hollow. Hollow microneedles having needle bore or lumen allow 
an active liquid transportation above the microneedle (Duan, 2013). Table 2 
includes different type of microneedles and its advantage and disadvantages.






titanium or glass, 
silicon)/ (Kolli, 
2008,Yuzhakov, 2007)
• Enhanced mechanical strength, 
efficacious insert, designed for 
various geometrical sizes as well 
as shapes 
Dual kinds: 
• Out of plane: permits 
greater density( per array) of 
microneedle as the shaft is 
perpendicular to base.
• In plane: the density of 
microneedle is restricted as 
the base plus shaft both lie in 
a similar plane.
• Drug distribution is diffusion 
mediated (lateral or vertical)
• Dissemination via microchannels 
(withdrawal of microneedle ) 
• Requirement of an 
expensive cleaning room 
facility for the complex 
manufacturing of silicon 
microneedles.




(Prausnitz, 2007, Gill, 
2007)
• Drug deposition into the depth 
of the skin 
• Drug delivery is usually not 
diffusion dependent.
• Single phase performances in 
case of drug distribution and 
microporation.
• does not dependent on additional 
microfluidics component or drug 
reservoir
• Successfulness is 
dependent on the 
procedure and formulation 
of coating.
• Coating of inequitable 
quantity which is 
appropriate solely in case 
of potent drugs
• Necessary to make sure 









• effortless and simple usage for 
drug distribution mechanism 
in case of finale user which is 
similar to that of passive patch
• comparatively little insensitive 
environment is required for 
coating rather than producing 
dissolvable micro moulding
• Appropriate in the distribution 
of vaccines or peptides, proteins
• Dose sparing is allowed.
• Amplified coat might 
negotiate for sharpness 











• Micro channels are formed 
within a minute after dissolution
• Dual kind: first is thru enclosed 
drug besides second is deprived 
of drug 
• Control drug discharge via 
slowly dissolvable polymers
• It is Biocompatible and 
biodegradable leading to 
reduction of irritability.
• No requirement for strident 
disposal of waste.
• Payload distribution is achieved 
on a larger scale as compared to 
coated microneedles.
• Drug is previously included 
in microneedles therefore no 
requirement for reconstituting 
drug.
• No reservoir leakage related issues
• Simple and reasonable 
micromoulding fabrication 
technique 
• In case of drug stability 
the techniques for 
fabrication are non 
conducive because 
of callous producing 
environment
• Insufficient drug filling 
capability 1mg for 1000 
microneedle
• Appropriate in case of 
entrapment for delicate 
macromolecules
• Need for ensuring that 
microneedles are left 
in skin or dissolved 
completely former to the 
extracting of the base 
or requirement of the 
applicator.
• Require cautious 
selectivity for ingredients 






• Distributing fluid preparations
• Placement of Drug at accurate 
depth inside the layers of skin.
• Quick start for action of drug is 
probable.
• High-priced fabrication 
method
• Condensed mechanical 
vigour in comparison to 
solid microneedles partic-
ularly prepared by silica.
• Clogging while inclusion 
through the tissues of skin.
• Outsized diameter of 
tip might link to poor 
inclusion
• Infusion rates restricted 











• Need renunciation 
followed by insert for 
helping the amplification 
of infusion rates
• Adjustment of required 
flow rate.
4.5 Advantages of micro-needle based vaccines
• Pain-free administration: Microneedles which have a length in a range 
of a few hundred micrometres could specifically permeate the superficial 
layers of the skin whose nerve receptors density is low. The outcome of 
this is that the insertion of microneedles within the skin is expected to be 
trouble-free (Gill, 2007)
• Easy to use: in case of a normal transdermal patch the patient himself could 
virtually apply an intended system without any required training. Moreover 
for attaining this distinct insertion any kind of tool and process parameters 
are not necessarily required. Therefore, a low insertion strength is required 
for microneedles and a consistent and vigorous technique is required for 
insertion. If it is attained then it is logical to consider that the process for 
numerous medication, can be sold over the counter (OTC) (Gill, 2007)
• Discreetness: Incorporating a microneedle-array along with a planar and 
compact medicating method yields a patch-like discreet device which 
could be slightly worn beneath the clothing (Gill, 2007).
• Continuous release: A non-obstructing device might be worn for larger 
time duration, hence allowing uninterrupted and constant delivery at 
therapeutic levels (Gill, 2007).
• Controlled release: Controlled release of drug can be achieved by 
the incorporation of passive components, e.g. flow restrictors or flow 
membranes and some active devices such as closed loop systems. The 
delivery on the basis of time and amplitude can be modulated by the 
possibility of active dosing systems (Gill, 2007).
• Safer handling: Microneedles expanded for a few hundred micrometres 
from the surface show a very less risk of inadvertent needle sticking as 
compared to that of hypodermic needles. The danger of communication 
of blood-borne pathogens is very less as the microneedles are not able to 
reach the blood (Gill, 2007).
4.6 Rationale behind microneedles (Ita, 2015)
• Solid microneedles based patches of drug can be used for intensifying 





by punching holes in the skin, rubbing the drug over an area or coating 
needles by the mediator to be circulated.
• Hollow needles can be used with drug patches and metered pumps for the 
delivery of drugs at specific time interval. This type of microneedles could 
be used for removing fluid through the body required in case of analysis 
– like blood glucose quantitation and then for supplying insulin or other 
desired drugs in micro liter volumes. They are capable in dosing at a very 
accurate level, patterns for complex release, for the promotion of local 
delivery and enhancement in case of biological drug stability by storage 
in a micro volume which could be controlled precisely. Table 3 shows 
various transdermal formulations of various drugs (Akhtar, 2014) based 
on microneedle approach. 
Table 3 : Marketed transdermal formulations based on microneedles
S. No Product Carrier System Applications References
1 Anti-restenosis Microneedle patches Target drug delivery in 
atherosclerosis
(McAllister, 2000)
2 Insulin Microneedles patches Reduced glycerol level 
upto 80% within 4 
hours
(Srinivas, 2010)











Microneedle patches Enhanced immune 
response
(Mortant, 2004)
6 Insulin Array of solid 
microneedles
Increases insulin 
transdermal delivery to 




Microneedle array Repeatable penetration 
across epidermis
(Ghosh, 2013)
9 Naltrexone and 
diclofenac 
Microneedle array Effective transdermal 
delivery
(Donnell, 2009)
10 5- amino 
levulinic acid
Microneedle array Enhanced production 
of photosensitizer
(Back, 2011)
11 Phenylephrine Microneedle Enhancement in case 
of mean resting anal 
sphincter pressure
(Qiu, 2012)


















Sustained release of 
insulin
(Wermeling, 2008)
14 Naltrexone Microneedles Enhanced transdermal 
delivery
(Ito, 2006)








Sustained delivery of 
microneedles
(Pawar, 2012)
4.7 Present status of developments on microneedles
Gill et al. worked on the consistency of covering the complexes such as bovine 
serum albumin, calcein, plasmid DNA and vitamin Baltered vaccinia virus 
and micro particles (ranging from 1 to 20 μm in diameter) on both individual 
and arrays of microneedles to be used for a unique micron-scale dip-coating 
method(Gill, 2007).
Matriano et al. observed the usage of Microneedles coated by a dry-film of 
antigen for the delivery of ovalbumin by the model protein antigen by injecting 
them within the skin of shaved guinea pigs in vivo by means of a high-velocity 
injector (Matriano, 2002).
Lee et al.(Lee, 2010)had worked on microneedles compressed by proteins, 
DNA etc. which could blend inside the skin in case of bolus or sustained 
delivery without leaving any kind of bio hazardous sharp medical waste for 
transdermal drug delivery. These kind of dissolving microneedles could be 
made-up of polymers such as PVP (commonly used as plasma expander and 
therefore are harmless) to transport deactivated influenza virus in lyophilized 
form aimed for influenza vaccination that targets the transfer of vaccine to skin’s 
antigen presenting cells and generates a sturdy immune responses. Polylactic 
acid, polyglycolic acid along with their copolymers is extensively used in the 
production of decomposable polymer microneedle (Yuzhakov, 2010).
Therefore, microneedles have been potential carrier for delivery of a number 
of drugs (enhanced transcutaneous permeation) and simultaneously these have 
been effectively utilized for more effective vaccine drug delivery systems.
Table 4 includes marketed products based on microneedle approach. 
Microneedles has been adopted as an approach for efficient delivery of various 
drugs such as lidocaine in pain management, nicotine for smoking cessation, 
nitroglycerin for angina etc. A list of products based on microneedle approach 
with the name of drug and disease has been compiled in table 5. Table 6 depicts 





been worked out using microneedles e.g. small pox, tuberculosis vaccine and 
various peptides (bovine serum albumin, growth hormone etc.) 
Table 4: Microneedle approach based patent edmarketed products
S. No. Product Company Name Description References
1 AdminPen® AdminMed Microneedle array based pen 
injector device.
(Desale, 2012)
2 AdminPatch® AdminMad Microneedle array (Desale, 2012)
3 Macroflux® Macroflux Microneedle array (Lax, 2010)
4 Microcore® Microcore Dissolved peptide 
microneedle patch
(Wu, 2012)
5 Microjet® Microjet Intradermal microneedle 
injection system.
(Wu, 2012)
Table 5: Data on FDA approved marketed products of various drugs based on 
microneedle approach 
Drug Product name Company Name Description








Fentanyl Duragesic Janssen Pain relief
Lidocaine Lidoderm Endo Post shingles pain


















Oxybutynin Emsam Watson Overactive bladder
Selegine Oxytrol Somerset Depression
















Small pox, T.B, 
yellow fever
Immense clinical study with smallpox, TB and various 
vaccines showed that vaccine delivery to human skin via 
conventional intradermal injection had been generally 
safe and effective and normally the similar immune 
response at low doses when compared to intramuscular 
injection.
Microneedles being used to deliver whole, inactivated 
virus, trivalent split antigen vaccines and may provide 






Stratum corneum is the main barrier to exogenous 
substances inclusive of drugs. Drugs having specific 
physicochemical properties can have successful 
transdermal administration.
There are various problems in transdermal delivery of 
hydrophilic drugs, molecular agents, peptides, DNA 
and RNA. Hence microneedles are used to puncture 
skin which will bypass the stratum corneum to create an 
aqueous transport pathway having micron dimensions 







The microneedle skin pre-treatment has various effects 
on drug transport depending on the type of formulation 
used, formulation characteristics show different effect 







Microneedles coupled with iontophoresis to have a 







blue or model 
vaccine 
ovalbumin
To evaluate a safe, ablative fractional laser based 
technology for enhancing transcutaneous delivery of 




DNA vaccine DNA vaccination in skin by microneedles improved 
protective immunity as compared to conventional 
intramuscular injection of plasmid DNA vaccine 
encoded for influenza hemagglutinin which was 
evaluated by in vivo fluorescence imaging that 
showed reporter gene being delivered to skin by solid 
microneedle patch coated with plasmid DNA.
At low dose vaccination via microneedles generated 
strong humoral response and good protective post 
challenge response being compared to IM vaccination 












Microneedles are being used for dermal and transdermal 
delivery of vide range of drugs and delivery of 
therapeutic proteins and vaccines.








Microneedles, micro array have been used in targeting, 
delivery of pharmacologically active compounds such 




DNA vaccines Microneedles have been developed to target intense 
network of immunologic antigen presenting cells in 
dermis and epidermis. Microneedles for wide range of 
vaccines having comparable or higher immunogenicity 
to conventional intramuscular route, having dose 
stability and dose sparing advantages.
Microneedle 
(Quinn, 2014)
Vaccine delivery Microneedles have been used to increase transdermal 
drug delivery by penetration into skins protective 
barriers by creating pathway for drug permeation to 





CD8 T cell Microneedle-mediated vaccine results in induction of 
low anti-vector antibody titres by permitting the repeated 
use of the same adenovirus vaccine vector,that resulted in 
significant increased antigen-specific antibody responses 
in mice as compared to ID-treated mice?
Microneedle array design don’t influence the magnitude 
of vaccine-induced antibody responses.
Microneedle 
(Chen, 2015)
Triptolide Microneedle technology is used for topical formulations 
to enhance the drug delivery .When triptolide is 
prepared as TP-LHP, the hepatic first-pass metabolism 
and digestive toxicity is eliminated.TP-LHP provides 
stable, long-term release of triptolide, and will have a 
significant efficacy in the CIA model. The combination 
of TP-LHP and microneedle technology can provide a 
safe and efficient method of administration of triptolide 






Microneedles are invasive devices that painlessly 
and without drawing blood penetrate into the skin’s 
stratum corneum barrier, these systems highly enhance 
the market size by removing dependence of efficient 
transdermal transport of drug physicochemical 
properties by allowing a wide range of drugs which 
can be delivered transdermally. microneedle arrays 
already have successfully delivered oligonucleotides, 
desmopressin, DNA, vaccines, insulin and human 
Growth hormone in vivo. They have advantages over 
conventional needle and syringe based on delivery 
systems for biological agents, particularly reduced pain, 












Microneedles are used to enhance transdermal drug 
delivery by fabricating in different forms: hollow, 
solid, and dissolving. There are also hydrogel-forming 
microneedles, being are innovative microneedles. They 
do not contain drugs but imbibe interstitial fluid to form 
continuous conduits Between dermal microcirculation 





CD8(+) T cells The use of novel ceramic nanoporous microneedle 
arrays (npMNA),served as a storage reservoir for 
vaccines. npMNA enhanced vaccine efficacy by more 





Vaccine delivery  A wide range of methods including FT-FIR using 
synchrotron radiation, nano indentation and skin 
delivery assays are used systematically to examine 
the effect of specific bulking agents and excipients, 
sugars /polyols for material form, structure, strength, 







This is an emerging and exciting area of pharmaceutical 
sciences research within the remit of transdermal drug
delivery highlighting some of the novel delivery systems 
which have been described in the literature exploiting 
these two approaches and directs the reader towards 
emerging uses for nanomedicines in combination with 
microneedles
5. CONCLUSION
Microneedles have been exploited as carrier for various drugs due to enhanced 
permeability thereby improved bioavailability and more patient compliance. 
This approach has also been adopted for delivery of vaccines but the success 
of microneedle approach for vaccine delivery is influenced by fabrication 
of device for infusion in to skin, the stability of the formulation and storage 
conditions required. 
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LIST OF ABBREVIATIONS 
ISCOM Immune stimulating complexes
TOLL A immune receptor
CpG Cytosine phosphate guanine
Quil A A adjuvant
MAP Multiple antigen peptide approach
CPP Cell penetrating peptide
MTP Membrane translocating peptides 
TAT Trans activator of transcription





DC-SIGN Dendritic cell specific ICAM-3 grabbing nonintegrin 
DEC 205 Dendritic cell receptor for endocytosis
L-SIGN Liver specific capture receptor for hepatitis C virus
MGL Macrophage galactose lectin
DNGR-1 Dendritic cell NK lectin group receptor 1
Clec 12A C type lectin like receptor
Clec 12B C- type lectin like receptor 
Clec 2 C- type lectin like receptor
DCIR Dendritic cell immunoactivating receptor
DC Dendritic cell
DC- STAMP Dendritic cell specific transmembrane protein
Fc receptor Fragment crystallisable
TLR TOLL like receptor
CCR1 Chemokine gene receptor 1
CCR2 Chemokine gene receptor 2
CCR5 Chemokine gene receptor 5
CCR6 Chemokine gene receptor 6
CXCR1 Chemokine gene receptor 1
CXCR4 Chemokine gene receptor 4
MALT Mucosally associated lymphoid tissues
SIV Simian immunodeficiency virus
DL-PLG Poly( DL-lactide –co –glycoside)
Bone marrow or bursa derived cells
SEB toxoid Staphylococcal enterotoxin B
IT route Intratracheal route
OTC Over the counter
PVP Poly vinyl propyledine
SRB Sulforhodamine B
ADHD Attention deficit hyperactivity disorder
AFL Ablative fractional laser
CIA Collagen induced arthritis
TP- LHP Triptolifde loaded liposome hydrogel patch
RA Rheumatoid arthritis
npMNA Nonporous microneedle array
GAVI Global Alliance for Vaccines and Immunization
